Indeed, it is critical to consider other relevant variables such as ovarian suppression for premenopausal women, genomic test results, ER or PR status, co-morbidities, the result of extended endocrine therapy, ovarian suppression particularly in <35-year-olds, adjuvant bisphosphonates in postmenopausal women, de-escalation of therapy in some subgroups such as HER2 positive patients with small tumours or patients who achieve pathological complete responses. Here, ERBB2 is linked to neoplasm.